PSIT-Pranveer Singh Institute of Technology (Pharmacy), Bhauti, Kanpur, UP, 209305, India.
Department of Pharmaceutics, Amity Institute of Pharmacy, Lucknow, Amity University, Uttar Pradesh, Sector 125, Noida, 201313, India.
Curr Diabetes Rev. 2024;20(6):e201023222414. doi: 10.2174/0115733998263079231011073803.
Type 2 diabetes mellitus (T2DM) is frequently referred to as a "lifestyle illness". In 2000, India (31.7 million) had the greatest global prevalence of diabetes mellitus, followed by China (20.8 million), the United States (17.7 million), and other countries. In recent years, the treatment of gene therapy (T2DM) has attracted intensive interest.
We aimed to critically review the literature on the various techniques and methods, which may be a possible novel approach through the gene therapy CRISPR Cas9 and some other gene editing techniques for T2DM. Interventional and pharmacological approaches for the treatment of T2DM were also included to identify novel therapies for its treatment.
An extensive literature survey was done on databases like PubMed, Elsevier, Science Direct and Springer.
It can be concluded from the study that recent advancements in gene-editing technologies, such as CRISPR Cas9, have opened new avenues for the development of novel therapeutic approaches for T2DM. CRISPR Cas9 is a powerful tool that enables precise and targeted modifications of the genome.
2 型糖尿病（T2DM）常被称为“生活方式病”。2000 年，印度（3170 万）的糖尿病全球患病率最高，其次是中国（2080 万）、美国（1770 万）和其他国家。近年来，基因治疗（T2DM）的治疗引起了广泛关注。
我们旨在批判性地回顾文献中关于各种技术和方法的内容，这些技术和方法可能是通过基因治疗 CRISPR Cas9 及其他一些基因编辑技术治疗 T2DM 的一种新方法。我们还纳入了 T2DM 的干预和药物治疗方法，以确定其治疗的新疗法。
我们在 PubMed、Elsevier、Science Direct 和 Springer 等数据库上进行了广泛的文献调查。
从这项研究可以得出结论，基因编辑技术（如 CRISPR Cas9）的最新进展为 T2DM 的新型治疗方法的开发开辟了新途径。CRISPR Cas9 是一种强大的工具，可实现基因组的精确和靶向修饰。
